Skip to main content

Find Clinical Trials

Home
Conditions
Paraproteinemias

Clinical trial condition

Paraproteinemias

Explore clinical trials studying Paraproteinemias. Study availability and eligibility vary by location and protocol.

3,004 public trials 571 recruiting studies

Refine in advanced search Browse all conditions

Paraproteinemias trial results

Not Yet Recruiting

A Study on the Use of Sulpegfilgrastim to Prevent the Incidence of Neutropenia With Infection in Newly Diagnosed Non-transplant Multiple Myeloma Patients

NCT07018271

Conditions: Agranulocytosis, Blood Protein Disorders, Cardiovascular Diseases, +19 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM Patients

NCT07015021

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Carfilzomib, +15 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

Comparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCT

NCT06963866

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations: The Affiliated Hospital oh Xuzhou Medical University Xuzhou, Jiangsu, China

View Trial Details

Not Yet Recruiting

Zanubrutinib Combined With BR in the First-line Treatment of Waldenström's Macroglobulinemia

NCT06942507

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations: Peking Union Medical College Hospital Beijing, China

View Trial Details

Not Yet Recruiting

Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)

NCT06931704

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: CHU Angers Angers, France

CH Côte Basque Bayonne, France

CHU Besançon Besançon, France

CHU Caen Caen, France

View all 36 locations

View Trial Details

Not Yet Recruiting

A Clinical Trial Evaluating the Safety Tolerability, Radiation Absorption Dose, Distribution, PET Imaging and Histological Expression of 68Ga-NOTA-SCH001 in Patients With Multiple Myeloma

NCT06925958

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

CAR-T Cell Therapy Combined With Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple Myeloma

NCT06913179

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

Efficacy of Sequential BCMA CAR-T Cell Therapy Following Autologous Hematopoietic Stem Cell Transplantation in Transplant-eligible Newly Diagnosed Multiple Myeloma

NCT06913192

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma

NCT06880601

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +19 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

Multiple Myeloma is a Hematologic Malignancy Characterized by the Accumulation of Malignant Plasma Cells in the Bone Marrow. Despite Advances in Treatment, Many Patients Experience Disease Relapse. Bispecific Antibodies Offer an Innovative Therapeutic Approach, But Approximately 30%-40% of Patients

NCT06888856

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations: Not specified

View Trial Details